This evidence of a direct stimulatory action of RA on NIS expression in thyroid cell lines, as well as the success in RA-redifferentiation prior to radioiodide therapy, encouraged investigators to study also the feasibility of radioiodide therapy after RA treatment in cancer patients with tumors of also other origins (61,62). This evidence concerns the gene SLC5A5 and cancer.